• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Lupin Ltd.
    05 Feb 2025
    US FDA Observation
    2055.60
    0.44%
    Lupin surges 8% in 2 days on USFDA nod for generic HIC drug
    Business Standard
    The drugs include Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets and the company is the exclusive first-to-file for this products
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.
    logo
    Sigachi Industries Ltd.
    05 Feb 2025
    44.20
    1.98%
    Small-cap stock under 50: Pharma stock jumps after CAPEX expansion update. Do you own?
    Small-cap stock under 50: Pharma stock jumps after CAPEX expansion update. Do you own?
    livemint
    Stock Market today: Small-cap stock under 50: Pharma stock Sigachi Industries share price is gaining momentum, buoyed by its recent CAPEX expansion for a R&D center. Analysts predict a price target, urging investors to watch closely as the stock aims to break past key resistance levels.
    Copy LinkShare onShare on Share on Share on
    Sigachi Industries Ltd. average weekly volume is high.
    logo
    Eris Lifesciences Ltd.
    05 Feb 2025
    1639.60
    0.21%
    Eris Life soars 13% on strong Q3 revenue; Co reduces debt ahead of guidance
    Business Standard
    The board of directors of Eris Lifesciences is scheduled to meet on Friday, February 07, 2025, to consider the declaration of interim dividend for the financial year 2024-25
    Copy LinkShare onShare on Share on Share on
    Eris Lifesciences Ltd. is trading below its 30 day SMA of 1723.6
    Eris Lifesciences Q3FY25 results: Profit skids 18.6%, revenue up 49.6%
    Business Standard | 04 Feb 2025 1 more
    Eris Lifesciences shares drop 5% after profit slides in Q3 results; details
    Business Standard | 04 Feb 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    05 Feb 2025
    1656.00
    0.45%
    Dividend, Stock-split: Sun Pharma, Ksolves, 5 others to go ex-date tomorrow
    Business Standard
    Here are the complete details of companies whose shares will trade ex-date tomorrow, along with their corporate announcements and key details
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical Industries Ltd. is trading above its 50 day SMA of 1639.2
    logo
    J B Chemicals & Pharmaceuticals Ltd.
    04 Feb 2025
    1714.20
    1.38%
    JB Chemicals Q3 Results: Profit Rises 22%, Declares Dividend Of Rs 8.50 Apiece
    JB Chemicals Q3 Results: Profit Rises 22%, Declares Dividend Of Rs 8.50 Apiece
    NDTV Profit
    Its margins remained flat at 26.4% for the quarter under review.
    Copy LinkShare onShare on Share on Share on
    J B Chemicals & Pharmaceuticals Ltd.'s price crossed above 50Day SMA today
    JB Chemicals Q3 results: Profit rises 21.6% to Rs 162 cr, revenue up 14%
    Business Standard | 04 Feb 2025 1 more
    JB Chemicals Q3 PAT rises 21 pc to 162 cr
    livemint | 04 Feb 2025
    logo
    Pfizer Ltd.
    04 Feb 2025
    5107.50
    -1.64%
    Pfizer beats profit estimates on heart disease drug, Covid vaccine sales
    Business Standard
    Pfizer is facing investor pressure to show that its recent acquisitions and investments can bring in returns
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. is trading above its 200 day SMA of 4895.2
    logo
    Gland Pharma Ltd.
    04 Feb 2025
    2022.80
    0.31%
    Gland Pharma shares slip 5% on disappointing revenue growth in Q3
    Business Standard
    Analysts at InCred Equities said they are disappointed with the repeated delay in Cenexi's turnaround and will reassess the situation constructively once the facility is back on track
    Copy LinkShare onShare on Share on Share on
    Gland Pharma Ltd. is trading above all available SMAs
    Gland Pharma Q3 Results Review - Motilal Oswal Reiterates 'Buy' On New Launches, Higher Milestone Income
    NDTV Profit | 04 Feb 2025 2 more
    Gland Pharma Q3 net up 7% at 205 cr
    Business Line | 03 Feb 2025
    Gland Pharma Q3 Results: Profit Rises 7%, Revenue Falls 10%
    NDTV Profit | 03 Feb 2025
    logo
    Alembic Pharmaceuticals Ltd.
    04 Feb 2025
    959.00
    0.17%
    Alembic Pharma Q3 Review - Dolat Capital Maintains 'Reduce' On The Stock, Revises Target Price Here's Why
    Alembic Pharma Q3 Review - Dolat Capital Maintains 'Reduce' On The Stock, Revises Target Price Here's Why
    NDTV Profit
    With limited upside, the brokerage maintains Reduce' rating with revised target price of Rs 1,004 at 22 times FY27E P/E.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr
    Alembic Pharma Q3 results: PAT falls 23.29% amid market headwinds
    Business Standard | 03 Feb 2025 2 more
    Alembic Pharma Q3 result: Profit dips 23% to Rs 138 cr on weak sales
    Business Standard | 03 Feb 2025
    Alembic Pharma Q3 Results: Consolidated net profit declines 23% to 138 crore, stock down 5%
    livemint | 03 Feb 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    03 Feb 2025
    1656.00
    0.45%
    Sun Pharma Elevates Aalok Shanghvi As Chief Operating Officer
    Sun Pharma Elevates Aalok Shanghvi As Chief Operating Officer
    NDTV Profit
    Aalok Shanghvi is currently designated as Whole-time Director and Executive Vice-President, Emerging Markets, Global Generic R&D, Global Business Development (Generics), Operations and API.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr
    Sun Pharma elevates promoter's son Aalok Shanghvi as COO
    Business Line | 03 Feb 2025
    logo
    Cipla Ltd.
    03 Feb 2025
    1575.80
    -0.15%
    Cipla To Invest Rs 415 Crore In South African Arm To Improve Capital Structure
    Cipla To Invest Rs 415 Crore In South African Arm To Improve Capital Structure
    NDTV Profit
    Cipla Medpro is responsible for the manufacturing, marketing, and supply of pharmaceutical products in South Africa.
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. has an average target of 1702.60 from 10 brokers.
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • JD Cables
    • GK Energy
    • Siddhi Cotspin
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd